Back to Search Start Over

Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE).

Authors :
Sonneveld, Milan J.
Park, Jun Yong
Kaewdech, Apichat
Seto, Wai-Kay
Tanaka, Yasuhito
Carey, Ivana
Papatheodoridi, Margarita
van Bömmel, Florian
Berg, Thomas
Zoulim, Fabien
Ahn, Sang Hoon
Dalekos, George N.
Erler, Nicole S.
Höner zu Siederdissen, Christoph
Wedemeyer, Heiner
Cornberg, Markus
Yuen, Man-Fung
Agarwal, Kosh
Boonstra, Andre
Buti, Maria
Source :
Clinical Gastroenterology & Hepatology; Apr2022, Vol. 20 Issue 4, pe784-e793, 10p
Publication Year :
2022

Abstract

Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels of hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg) and outcome after therapy cessation. Patients who discontinued NA therapy in centers in Asia and Europe were enrolled. HBcrAg and HBsAg were measured at treatment cessation, and associations with off-treatment outcomes were explored. The SCALE-B (Surface antigen, Core-related antigen, Age, ALT, and tenofovir for HBV) score was calculated as previously reported. End points included sustained virologic response (VR; hepatitis B virus DNA level <2000 IU/mL), HBsAg loss, and alanine aminotransferase (ALT) flares (>3× upper limit of normal). Re-treated patients were considered nonresponders. We analyzed 572 patients, 457 (80%) were Asian and 95 (17%) were hepatitis B e antigen positive at the start of NA therapy. The median treatment duration was 295 weeks. VR was observed in 267 (47%), HBsAg loss was observed in 24 (4.2%), and ALT flare was observed in 92 (16%). VR (67% vs 42%) and HBsAg loss (15% vs 1.5%) was observed more frequently in non-Asian patients when compared to Asian patients (P <.001). Lower HBcrAg levels were associated with higher rates of VR (odds ratio [OR], 0.701; P <.001) and HBsAg loss (OR, 0.476; P <.001), and lower rates of ALT flares (OR, 1.288; P =.005). Similar results were observed with HBsAg (VR: OR, 0.812; P =.011; HBsAg loss: OR, 0.380; P <.001; and ALT flare: OR, 1.833; P <.001). Lower SCALE-B scores were associated with higher rates of VR, HBsAg loss, and lower rates of ALT flares in both Asian and non-Asian patients (P <.001). In this multicenter study, off-treatment outcomes after NA cessation varied with ethnicity. Lower levels of HBcrAg and HBsAg were associated with favorable outcomes. A risk score comprising both factors can be used for risk stratification. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15423565
Volume :
20
Issue :
4
Database :
Supplemental Index
Journal :
Clinical Gastroenterology & Hepatology
Publication Type :
Academic Journal
Accession number :
155725332
Full Text :
https://doi.org/10.1016/j.cgh.2020.12.005